In a transgender male receiving intramuscular testosterone 75 mg every two weeks with a total testosterone of 927 ng/dL and free testosterone of 180 pg/mL, what is the appropriate next step in management?

Dose Reduction Required for Supraphysiologic Testosterone Levels

Your patient's testosterone levels are dangerously high at 927 ng/dL total and 180 pg/mL free—both well above the therapeutic target—and the dose must be reduced immediately to 25–37.5 mg every 2 weeks to prevent erythrocytosis and other adverse effects. 1

---

Why Dose Reduction Is Mandatory

• Target testosterone levels during therapy are 450–600 ng/dL (mid-normal range), measured midway between injections. 1, 2
• Your patient's total testosterone of 927 ng/dL is 55% above the upper target and places him at significantly elevated risk for erythrocytosis, which occurs in up to 44% of patients on injectable testosterone. 1, 3
• Supraphysiologic testosterone levels (>1,000 ng/dL) markedly increase adverse event risk, particularly hematocrit elevation that can aggravate coronary, cerebrovascular, and peripheral vascular disease. 1, 3
• The current 75 mg every 2 weeks regimen is producing levels that exceed therapeutic goals; continuing this dose despite "feeling well" is inappropriate because objective harm (erythrocytosis, cardiovascular risk) can occur asymptomatically. 1, 2

---

Specific Dose Adjustment Strategy

Immediate Action

• Reduce the dose by approximately 50–67% to 25–37.5 mg every 2 weeks as the initial adjustment, given that the current level is nearly double the target mid-normal value. 1, 2
• Alternatively, switch to weekly dosing at 12.5–18.75 mg per week, which provides more stable testosterone levels and reduces the "roller-coaster" effect that contributes to erythrocytosis risk. 1, 2

Formulation Considerations

• Strongly consider switching from intramuscular injections to transdermal testosterone gel (1.62%, ≈40 mg daily), which carries a markedly lower erythrocytosis risk (15.4% vs. 43.8% with injectable formulations) and provides more consistent day-to-day levels. 1, 2
• If cost is a barrier (transdermal ≈$2,135/year vs. injectable ≈$156/year), then proceed with dose-reduced injectable therapy but monitor hematocrit closely. 1

---

Monitoring Protocol After Dose Adjustment

Initial Follow-Up (2–3 Months)

• Measure total testosterone midway between injections (days 5–7 for weekly dosing or days 7–10 for bi-weekly dosing), targeting 450–600 ng/dL. 1, 2
• Check hematocrit/hemoglobin; withhold testosterone entirely if hematocrit exceeds 54% and consider therapeutic phlebotomy in high-risk patients. 1, 2
• Reassess free testosterone if total testosterone remains borderline, especially given the patient's transgender status where SHBG may be altered. 1

Ongoing Monitoring (Every 3–6 Months During First Year, Then Annually)

• Repeat total testosterone, hematocrit, and PSA (if >40 years old). 1, 2
• Refer to urology if PSA rises >1.0 ng/mL within the first 6 months or >0.4 ng/mL per year thereafter. 1
• Perform digital rectal examination at each visit. 1

---

Expected Outcomes with Dose Reduction

• Testosterone levels should normalize to 450–600 ng/dL within 2–3 months after dose adjustment, maintaining therapeutic benefit while minimizing adverse effects. 1, 2
• Erythrocytosis risk will decrease substantially once supraphysiologic peaks are eliminated; injectable testosterone produces peaks 2–5 days post-injection that drive hematocrit elevation. 1, 2
• Clinical benefits (libido, sexual function) are maintained at mid-normal testosterone levels; there is no additional benefit from supraphysiologic concentrations. 1

---

Critical Pitfalls to Avoid

• Do not continue the current 75 mg every 2 weeks dose even if the patient reports subjective well-being; objective harm (erythrocytosis, cardiovascular risk) occurs independently of symptoms. 1, 2
• Do not stop testosterone therapy abruptly if the patient was initially hypogonadal; dose reduction—not discontinuation—is the appropriate intervention. 1, 2
• Do not draw testosterone levels at the peak (days 2–5 post-injection), as this will show even higher supraphysiologic levels and does not reflect average exposure. 1
• Do not ignore hematocrit monitoring; injectable testosterone carries a 43.8% erythrocytosis incidence, and elevated hematocrit increases blood viscosity and thrombotic risk. 1, 3
• Do not assume all transgender men require the same dose; individualized dosing based on serum levels—not fixed protocols—is mandatory. 1, 2

---

Alternative: Switch to Transdermal Formulation

• If erythrocytosis develops or hematocrit trends upward (>50%), switch to transdermal testosterone gel rather than continuing dose-reduced injectable therapy. 1, 2
• Transdermal testosterone 1.62% gel (starting at 20.25–40.5 mg daily) provides stable serum levels, a lower erythrocytosis risk (15.4% vs. 43.8%), and easier dose titration. 1, 2
• Monitor testosterone levels 2–3 months after switching formulations to confirm target mid-normal values are achieved. 1, 2